SYDNEY — Australia's benchmark S&P/ASX 200 index closed essentially unchanged Monday, slipping just 3.3 points, or 0.04%, to settle at 8,820.1, after a session that swung between gains and losses before ultimately finishing close to where it started.

The muted overall result masked considerable movement beneath the surface, with the index briefly testing red territory during the session before investors regained their footing, building on momentum from the prior week. Closing figures from Monday put the index at slightly different levels depending on the data provider, with some pegging the final close at 8,823.4, a gain of roughly 0.68% on the day, reflecting the kind of cross-source discrepancies common when index data is sourced from different real-time feeds.

The day's standout performer, by a wide margin, was Neuren Pharmaceuticals, which rocketed 36.07% to close at $16.60 after the company announced a major regulatory breakthrough in Europe tied to its Rett syndrome treatment. The healthcare sector overall benefited from that surge, with the S&P/ASX 200 Healthcare Index trading comfortably above its 50-day moving average for the first time since last August and sitting up roughly 16.6% since early June, underscoring just how much of the sector's recent strength has been concentrated in a handful of major biotech announcements.

Beyond healthcare, gains were broad-based across most major sectors. Financial stocks climbed between 0.75% and 0.9% to 1.4%, with all four of Australia's major........

© International Business Times